Clinical trial NCT01750502: The Clinical Diagnosis Meaning of MIF in Coronary Heart Disease
Official title: MIF Gene Polymorphism in Coronary Heart Disease：Clinical Meaning
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Heart Disease
Lead sponsor: Wenzhou Medical University
Sponsor class: OTHER
First posted: 2012-12-17
Enrollment: 256
Sex: ALL
Minimum age (years): 20
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Second Hispital of Wenzhou Medical College outpatient and inpatient

Brief summary: Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine that promote the inflammatory response.In animal studies, it has been found that MIF is released in the ischaemic heart, promoting glucose uptake and protecting the heart from ischaemia-reperfusion injury.The MIF concentration, influenced by age and myocardial ischemia, have different impact on myocardial functional recovery after ischemia.Therefore, the purpose of this experiment is to study the clinical significance of MIF in patients with coronary heart disease.

Detailed description: MIF is a pleiotropic cytokine that promote the inflammatory response. MIF is expressed in several cell types,including monocytes/macrophages, vascular smooth muscle and cardiomyocytes, and is released on stimulation from pre-formed storage pools. A foreign study reported that MIF had demonstrated to offer protection from I/R-injury by activating adenosine monophosphate-activated protein kinase (AMPK) and inhibiting c-Jun Nterminal kinase (JNK)-induced apoptosis of cardiomyocytes. In addition, animal experiments showed that MIF was reduced in aged heart compared with young heart. Coronary heart disease is a chronic ischemic disease, in which MIF may play as a protective factor during the whole procedure.

We observed individuals who will be taking coronary angiography during the hospitalization. Individuals will be assigned to coronary-artery-disease group, which included acute coronary syndromes and stable ischemic heart disease, or non-coronary-artery-disease group, according to coronary angiography. All participants will be extracted 3ml blood sample 5 minutes before coronary angiography. Coronary-artery-disease group will be taken another two blood samples, 5 minutes after the opening of the balloon and 5 minutes after the stents have been implanted, respectively.

Eligibility criteria: Inclusion Criteria:

Control group:

1. enroll individuals who confirmed by coronary angiography without coronary heart
2. The age between 20 and 80 years old.
3. Alanine aminotransferase(ALT):10-55U/L, Aspartate aminotransferase(AST):0-60U/L
4. Glucose(GLU-S):3.9-6.1mmol/L
5. Triglycerides(TRIG):0.56-1.7mmol/L, cholesterol(CHOL):3.1-5.2mmol/L, High density lipoprotein(HDL):0.78-1.96mmol/L, High density lipoprotein(LDL):2.07-3.1mmol/L

Experimental group:

1. enroll individuals who confirmed by coronary angiography for coronary heart
2. The age between 20 and 80 years old.
3. ALT:10-55U/L,AST:0-60U/L
4. GLU-S:3.9-6.1mmol/L
5. TRIG:0.56-1.7mmol/L,CHOL:3.1-5.2mmol/L,HDL:0.78-1.96mmol/L,LDL:2.07-3.1mmol/L

Exclusion Criteria:

1. Inflammatory diseases,such as rheumatoid arthritis,sepsis,asthma and acute respiratory distress syndrome.
2. Diabetes

Primary outcomes:
measure: Comparison Between Coronary-artery-disease Group and Non-coronary-artery-disease Group on MIF Concentration
timeFrame: Before surgery 5 minutes
Secondary outcomes:
measure: Comparison the Change of MIF Before and After Percutaneous Coronary Intervention （PCI） at the Patients Who Are Acute Coronary Syndromes and Stable Ischemic Heart Disease
timeFrame: 3 times including before surgery 5 minutes, 5 minutes after the opening of the balloon and after surgery 5 minutes
Other outcomes:
measure: Comparison With MIF-173G/C Genotypes of CHD Patients and Controls.
timeFrame: Before surgery
measure: Comparison of MIF-173G/C Alleles of CHD Patients and Controls.
timeFrame: Before surgery
Locations:
city: Wenzhou
country: China
facility: Second Hispital of Wenzhou Medical College
state: Zhejiang
Study officials:
affiliation: Wenzhou Medical University
name: Jifei Tang, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Qian L, Wang XY, Thapa S, Tao LY, Wu SZ, Luo GJ, Wang LP, Wang JN, Wang J, Li J, Tang JF, Ji KT. Macrophage migration inhibitory factor promoter polymorphisms (-794 CATT5-8): Relationship with soluble MIF levels in coronary atherosclerotic disease subjects. BMC Cardiovasc Disord. 2017 Jun 2;17(1):144. doi: 10.1186/s12872-017-0570-x.
citation: Ji K, Wang X, Li J, Lu Q, Wang G, Xue Y, Zhang S, Qian L, Wu W, Zhu Y, Wang L, Liao L, Tang J. Macrophage migration inhibitory factor polymorphism is associated with susceptibility to inflammatory coronary heart disease. Biomed Res Int. 2015;2015:315174. doi: 10.1155/2015/315174. Epub 2015 Mar 4.